Lighting the Way: A Calgary Startup Tackles One of Canada’s Biggest Environmental Challenges
In northern Alberta, one of the most complex environmental challenges in the world continues to grow quietly but persistently. More than a trillion litres of oil sands tailings water sit across vast landscapes, awaiting a viable path to treatment and eventual release. For decades, one of the most significant barriers has been deceptively simple: understanding what is in that water quickly, accurately, and affordably enough to take meaningful action.
That’s where Luminous BioSolutions comes in.
Founded in April 2025, this early-stage Alberta startup is tackling a problem that has long resisted innovation. Its focus is on detecting naphthenic acids, a key contaminant in oil sands tailings water, in a way that is faster, more cost-effective, and scalable for real-world use. While the company is still pre-seed and pre-revenue, its technology is already attracting the attention of major industry players and regulators alike.
Its journey from academic research to commercialization tells a powerful story of how early-stage investment can shape outcomes, and how Genome Alberta’s support helped accelerate the path from research to commercial readiness.
A Decade in the Making
Luminous BioSolutions did not emerge overnight. It is the product of more than a decade of applied research, now reaching an inflection point where scientific depth and commercial opportunity align.
Co-founder Shawn Lewenza, a researcher with more than a decade of experience at the Athabasca University and the University of Calgary, along with over 20 years working in microbiology and antibiotic discovery, developed the company’s core innovation: a biosensor capable of detecting naphthenic acids (NA) using engineered bacteria that emit light in their presence. The result is a proprietary patent-protected platform with the potential to reshape how the oil sands industry approaches compliance, cost management, and environmental performance.
“The biosensor detects naphthenic acids using bacteria that literally light up, enabling rapid, high-volume, low-cost testing compared to traditional methods” says Shawn. “Where conventional testing relies on expensive, time-intensive analytical chemistry like mass spectrometry, our biosensor panel offers the potential for near real-time monitoring at a fraction of the cost, which will open the door to more consistent and widespread testing.”
“Our biosensors can detect NA and produce a semi-quantitative estimate of the total NA concentration. In addition, we have a biosensor that specifically detects the toxic membrane activity of naphthenic acids. This effectively targets two main industry problems, measuring NA amounts and their toxicity during remediation”.
Backed by a provisional patent filed in 2021, followed by a full patent application and a peer-reviewed publication in 2024, the technology has already moved beyond controlled laboratory settings and into real-world validation environments. Achieving this level of maturity required more than strong science. It required access, collaboration, and sustained investment.
The Role of Early-Stage Investment
The turning point came through a large, multi-partner Genome Canada project known as GROW, supported in part by Genome Alberta. This initiative brought together academic researchers, industry partners, and real-world testing environments, including access to constructed wetlands at an active oil sands site. In an industry where access to data and facilities is often limited, this level of collaboration was both rare and highly valuable.
“Without the support from Genome Alberta and Genome Canada, the technology would likely have remained a laboratory result rather than a commercially viable product” says Shawn.
Through the GROW project, the team was able to test their biosensor against gold-standard analytical methods using real industry samples. This head-to-head validation generated the type of robust data required to build credibility with investors, regulators, and potential customers.
Equally important, the project provided something that is often missing at the start-up stage: a clear pathway toward commercialization. In this case, early-stage funding enabled much more than discovery. It supported patent development, facilitated field validation, and produced the foundational publications that now underpin the company’s value proposition. It also connected the team with industry partners they needed to move forward.
Building a Market That Doesn’t Yet Exist
Today, Luminous BioSolutions is focused on a highly concentrated but critical market: Alberta’s oil sands operators and the opportunity is enormous, not just in scale, but in significance. An estimated 1.4 trillion litres of tailings water remain stored across roughly 300 square kilometres in northern Alberta. Naphthenic acids are a primary barrier to effectively treating and safely releasing that water, making reliable monitoring essential.
And yet, there’s a paradox, in that the market for this type of monitoring is still emerging.
“Historically, testing has been too expensive and time-consuming to conduct at high frequency, and regulatory requirements for routine monitoring have not yet been fully established” says Shawn. “Our latest study has shown that NA biosensors can act as a proxy and estimate the total NA concentrations similar to cutting edge analytical chemistry. As a result, we are not only introducing a new technology but one that could contribute to the regulatory guidelines which will enable its adoption. Early-stage investment isn’t just about developing technology; it’s about building the evidence base that drives the regulatory and commercial conditions under which that technology can succeed.”
This places Luminous BioSolutions at the intersection of science, policy, and industry. Its impact extends beyond technical innovation to include regulatory advancement and the strengthening of public confidence in environmental management.
From Data to Decisions
In addition to the biosensor itself, Luminous BioSolutions is developing a complementary software platform that integrates sensor data with environmental variables like temperature, precipitation, and pH. The objective is to provide operators with a more comprehensive understanding of water conditions and enable more informed decision-making.
By turning raw data into actionable intelligence, the platform can help operators optimize water treatment processes, support regulatory compliance, and provide greater transparency for communities concerned about environmental outcomes.
At the same time, the company is exploring a second, longer-term innovation pathway focused on bioremediation, by using naturally occurring bacteria to actively break down naphthenic acids in tailings water. Together, these technologies point toward a future where monitoring and remediation are integrated, and where environmental challenges can be addressed more proactively.
Impact Beyond the Balance Sheet
Even at the pre-revenue stage, the economic significance of Luminous BioSolutions is already taking shape. The company represents the early formation of a homegrown Alberta success story with the potential to create skilled jobs, attract private capital, and anchor a new sector of environmental technology within the province. That commercial case is reinforced by the fact that Luminous BioSolutions addresses a measurement challenge that has gone unsolved for decades, with no comparable solution currently on the market.
But perhaps most importantly, its work carries real implications for communities and the environment.
The ability to monitor naphthenic acid levels quickly, affordably, and at scale could play a critical role in enabling the safe treatment and eventual release of tailings water. This issue is of particular importance to Indigenous and local communities located near oil sands operations, where environmental outcomes are closely tied to health, livelihoods, and trust.
It’s a reminder that innovation is not solely about technological advancement. It is also about accountability, transparency, and delivering outcomes that matter to people.
A Model for What’s Possible
Luminous BioSolutions remains at the beginning of its journey, yet its trajectory already illustrates what can be achieved when early-stage research is supported effectively. With the right combination of funding, collaboration, and access to real-world environments, research investments can be converted into commercial products, high-value jobs, and lasting economic returns for Alberta.
Genome Alberta’s role in that journey was not just supportive, it was catalytic. By enabling the GROW project and fostering a collaborative ecosystem, Genome Alberta helped transform a promising idea into a validated technology, and a research program into a commercially viable company with a clear path to market.
For Luminous BioSolutions, that early support made all the difference.
And for Alberta and beyond, it demonstrates what is possible when Alberta invests strategically in life sciences commercialization supporting companies that solve environmental challenges, generate economic returns and contribute to a more diversified provincial economy.
Read more about Genome Alberta’s programs to support commercialization:
